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Abstract
Adaptive designs have the potential to improve efficiency in the evaluation of new medical treatments in
comparison to traditional fixed sample size designs. However, they are still not widely used in practice in clinical
research. Little research has been conducted to investigate what adaptive designs are being undertaken. This review
highlights the current state of registered adaptive designs and their characteristics. The review looked at phase II, II/III
and III trials registered on ClinicalTrials.gov from 29 February 2000 to 1 June 2014, supplemented with trials from the
National Institute for Health Research register and known adaptive trials. A range of adaptive design search terms
were applied to the trials extracted from each database. Characteristics of the adaptive designs were then recorded
including funder, therapeutic area and type of adaptation. The results in the paper suggest that the use of adaptive
designs has increased. They seem to be most often used in phase II trials and in oncology. In phase III trials, the most
popular form of adaptation is the group sequential design. The review failed to capture all trials with adaptive designs,
which suggests that the reporting of adaptive designs, such as in clinical trials registers, needs much improving. We
recommend that clinical trial registers should contain sections dedicated to the type and scope of the adaptation and
that the term ‘adaptive design’ should be included in the trial title or at least in the brief summary or design sections.
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Background
Adaptive designs (ADs) have the potential to improve effi-
ciency in the evaluation of new medical treatments in
practice and alleviate some of the shortcomings of fixed
sample size designed trials when used appropriately [1].
However, ADs are not widely used routinely in clinical
trial research despite the prominence given to them in
the statistical literature [2–5]. Initiatives, predominately
from a pharmaceutical drug development perspective,
have been undertaken to understand and address some
of the perceived barriers to the uptake of ADs in rou-
tine practice when they are considered appropriate [5–9].
Most importantly in this sector, regulatory bodies have
drafted guidance documents or reflection papers on ADs
to facilitate their use [6, 10–12].
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Whilst it would be logical to infer that these initiatives
would lead to an increase in the application of ADs, lit-
tle research has been done to investigate if this is the
case [2, 8, 13, 14]. Advocates for ADs suggest their use is
increasing while opponents say otherwise [1, 15].
Recent studies have highlighted barriers to the use of
ADs including: a lack of practical knowledge and expe-
rience, insufficient access to case studies of ADs, lack
of awareness of types of AD, unfamiliarity with ADs
and fear of jeopardising chances of regulatory approval
[4, 5, 16, 17].
The perceived barriers led to the motivation for this
study, which aims to review the types of registered ADs in
use and explore in more detail their characteristics. The
objective of the review in this paper is to highlight the cur-
rent state of ADs and raise awareness regarding the type
of ADs being implemented in clinical trial research. The
specific objectives of this review are to explore:
1. The number of trials designed and conducted as ADs
2. The type of ADs being implemented with particular
emphasis on confirmatory trials
© 2016 Hatfield et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
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3. The most common therapeutic areas where certain
types of ADs are being used
4. The distribution of ADs by geographic location, trial
phase and funder or sponsor
5. The trial characteristics of ADs
6. Trends in the use of ADs by trial phase and funder
7. The adequacy of ClinicalTrials.gov [18] in capturing
AD trials
Methods
Literature search
The World Health Organization (WHO) register [19] was
used to carry out a feasibility study. The results informed
the choice of databases for the main review, which
involved searching the ClinicalTrials.gov database [18]
and the National Institute for Health Research (NIHR)
database [20] for AD trials, subject to pre-specified inclu-
sion criteria. The search was restricted to dates between
29 February 2000 (when ClinicalTrials.gov [18] became
available to the public) and 1 June 2014.
Feasibility
A comprehensive feasibility study was conducted using
the WHO register [19]. Trials registered on 25 June from
the years 2009 to 2013 inclusive were chosen for this exer-
cise. The date, 25 June, was randomly selected using R
Studio and the years restricted to 2009 to 2013 because
time constraints required us to limit the number of tri-
als reviewed and we anticipated the number of ADs being
larger in more recent years. For trials satisfying the main
study inclusion criteria (details presented in the Eligibility
criteria section), two reviewers (AA and LF) indepen-
dently and manually ascertained whether they could be
classified as adaptive or not. Decisions were aided by any
available material related to the study such as protocols
and publications.
A list of AD related search terms was applied to all
trials meeting the inclusion criteria to check whether
the adaptive trials found manually were also identified
using the search terms. Due to the restrictive nature of
the searching algorithm of the WHO register (limited
to lay and scientific titles), there was poor agreement
between the two approaches. Thus, any trials that did
not highlight the adaptive nature of the study in these
titles would not be identified by the search. The search
terms were updated based on these findings as illustrated
in Fig. 1. In addition, trial phase could not be ascer-
tained for a large proportion of trials and the adaptive
nature of the trials was not often described in detail or
missing, implying a major limitation of using the WHO
register. Hence, themain reviewwas restricted to Clinical-
Trials.gov [18], as it has better flexibility and is improved
in filtering records, data completeness and searching
options.
Search strategy
A list of AD related search terms was compiled (see
Additional file 1). This was an iterative process (see Fig. 1)
with the chosen terms based on results from the feasi-
bility study, the opinions of experts in the field of ADs
[21] and a scoping exercise using ClinicalTrials.gov [18]
to eliminate redundant terms. The search terms were
applied to trials meeting the inclusion criteria using the
Boolean OR operator. These were then extracted and one
reviewer (IH) confirmed whether the trials were truly
adaptive in design in consultation with other researchers
(LF and MD) when necessary, as a form of quality
control.
Data sources
The main source for the review was ClinicalTrials.gov
[18], as it is a large database and includes unpublished tri-
als. We decided to use ClinicalTrials.gov [18], as opposed
to peer-reviewed publications, as it has the potential for
real-time data capture, thus reducing the time lag between
trial commencement and publication, which can take a
number of years. It also has the potential to reduce the
publication bias found in peer-reviewed journals – pos-
itive findings of successful trials are more likely to be
published than those with negative findings [22]. This
could potentially downplay the number of ADs as one
of their main features is the ability to stop trials for
futility, i.e. if the results are negative. In contrast, reg-
istration of all trials is now mandatory, so using Clin-
icalTrials.gov [18] will obviate this problem provided
the information given is complete. The database does
have its own limitations, however, and so the search
from ClinicalTrials.gov [18] was supplemented with tri-
als identified from the NIHR register [20], which contains
more information, and known adaptive trials from con-
tacts with trialists within the pharmaceutical and public
sector.
For the latter, contacts were made through person-
alised emails, specialised group emails (such as MedStats,
Google group and the UK CTU infrastructure network of
senior statisticians), and specialised group posts (such as
LinkedIn targeting Statistics in the Pharmaceutical Indus-
try and ADs working groups – 1601 members as of 10
July 2014). Originally, it was intended to include Medical
Research Council (MRC) funded trials as supplementary
material. However, it was not possible to find an up-to-
date list of trials for this funding body and so these could
not be included in the review.
Trials from the two supplementary sources were linked
back to ClinicalTrials.gov [18] to extract additional infor-
mation of interest. Duplicates were checked using the
unique trial registration number and removed before
analysis. The data source was left-truncated at 29
February 2000 and right-truncated on 1 June 2014.
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Fig. 1 Search strategy. A flow diagram of the decision-making process used to determine the search terms.WHOWorld Health Organization
Dealing withmissing data
Chief investigators were contacted with a request to
respond within 4 weeks to reduce missing data. If the
missing information was needed to determine whether or
not the trial design was adaptive, the trial was excluded
from the review. If the trial was known to be adaptive
but some other information wasmissing (e.g. sample size),
the trial was included in the review but missing data
highlighted.
Eligibility criteria
Clinical trials were eligible to be included if the following
criteria were satisfied:
• The trial investigates an intervention(s) on humans
with a comparator.
• It is phase II, III or II/III.
• It was left-truncated on 29 February 2000 and
right-truncated on 1 June 2014.
• Trial documents are written in English.
Quality control
A second reviewer (MD) validated all phase III ADs and
two reviewers (LF and MD) validated any other trials
where clarification was required.
To assess the adequacy of ClinicalTrials.gov [18] in cap-
turing AD trials, a search of published trials using MED-
LINE was performed. With MEDLINE, it is possible to
search the abstracts and titles of published trials more
comprehensively than with ClinicalTrials.gov [18]. The
anticipation is that more trials would be found through
this route. Its main limitation is that it does not have
ongoing trials unless the trial has published the protocol.
The filters ‘English’, ‘humans’, ‘2000 to current’, ‘clinical
trial all’, ‘controlled clinical trial’, ‘pragmatic clinical trial’,
‘randomised controlled trial’ (RCT) and ‘full-text’ were
applied, giving 2079 trials (as of 1 June 2014). A random
sample of 300 trials was selected and the design and phase
of the trials extracted by three reviewers (MD, AA and
LF). The registration of any AD trials on ClinicalTrials.gov
[18] was checked and a search of those trials included
in the review undertaken to ascertain the number
and percentage of ADs missed and picked up by the
search.
Data collection
The following information was collected from the
included trials and recorded on an Excel spreadsheet:
• Whether the trial was truly adaptive and the nature
of the adaptation if so
• The stopping rule, for example, futility or efficacy
• The year of registration and completion
• The nature and duration of the primary outcome
• The expected total sample size
• The scope of the study (national or international)
• The country of the lead chief investigator
• The nature of the experimental intervention and the
comparator and the number of treatment arms
• The funder or sponsor of the study
• The current state of the trial, for example,
terminated, ongoing or completed
• The therapeutic area under study
• The population under study
• Whether or not the trial is published
• Reason for termination on those trials that
terminated early
For phase III trials, additional information was also col-
lected:
• Other design characteristics, for example, parallel
group
• Nature of the primary hypothesis of interest, for
example, superiority
Main outcomemeasures
The main outcome measures were:
1. The types of ADs
2. The frequency of ADs
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Outline of analyses
We used descriptive summary statistics depending on
the nature of the variables and graphs for presenta-
tion. Results were also stratified by phase and funder.
The number of ADs per 10,000 registered trials by time
period and 95 % confidence intervals (CIs) were pro-
duced and graphed to explore the trend in the use of
ADs.
Results
Study selection
As of 1 June 2014, 159,645 trials were registered on Clin-
icalTrials.gov [18] and approximately 2300 on the NIHR
register [20]. Of these, 554 were assessed for eligibility
together with 19 known adaptive trials. Only 158 were eli-
gible for further review and analysis. Among the reasons
for ineligibility were: not adaptive in design (n = 246),
phase I or IV (n = 128), observational study (n = 1),
NIHR retrospective reviews (n = 26) and duplicates (i.e.
known trials that were already captured in the search)
(n = 14). A further 15 trials were excluded from the anal-
ysis because information required to determine the trial
design was missing, leaving a total of 143 trials for the
analysis. Figure 2 shows a flow diagram of the screening
process. Table 1 describes a sample of trials included in
the review.
Registered trials as of 1st June 2014
(n = 161 945)
clinicaltrials.gov (n = 159 645)
NIHR (n ≈ 2300)
Retrieved and assessed for eligibility
(n = 573)
clinicaltrials.gov (n = 428)
NIHR (n = 126)
Known adaptive trials (n = 19)
Ineligible (n = 415)
Not adaptive in design (n = 246)
clinicaltrials.gov (n = 193)
NIHR (n = 53)
Phase I or IV (n = 128)
clinicaltrials.gov (n = 96)
NIHR (n = 31)
Known adaptive trials (n = 1)
Observational study (n = 1)
NIHR (n = 1)
NIHR retrospective reviews (n =
26)
Duplicates (n = 14)
Eligible (n = 158)
Excluded (n = 15)
No data available (n = 15)
clinicaltrials.gov (n = 14)
NIHR (n = 1)
Analysed (n = 143)
clinicaltrials.gov (n = 125)
NIHR (n = 14)
Known adaptive trials (n = 4)
Fig. 2 Screening process. A flow diagram showing the review process including reasons for exclusion of trials. NIHR National Institute for Health
Research
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Table 1 Brief descriptions of a sample of identified confirmatory ADs captured in the review
Trial registration number Description
NCTO1230775 This is a private-sector-funded two-stage confirmatory AD with sample size re-estimation (SSR) at the first
interim analysis applying the methodology proposed by Bauer and Kohne [25] using P value combination
procedures. It is a double-blinded RCT investigating the efficacy and safety of a drug Anagrelide Retard in
patients with essential thrombocythaemia at certain defined risk criteria.
NCT01555710 The MATISSE study is a private-sector-sponsored open-label RCT with an active comparator, adaptive
group sequential design (GSD) with SSR at the interim analysis evaluating the efficacy of palifosfamide-tris,
in combination with carboplatin and etoposide chemotherapy in chemotherapy naive patients with
extensive-stage small-cell lung cancer.
NCT00268476 The STAMPEDE study is a phase II/III RCT with a multi-arm multi-stage AD investigating five treatments in
combination with hormone therapy for patients with locally advanced or metastatic prostate cancer with
options to drop futile arms or add new investigation arms during the trial. The trial is predominantly funded
by the UK public sector. Sydes et al. [26, 27] describe the rationale and design aspects of the trial. James
et al. [28] present the first interim results with decisions to discontinue certain intervention arms.
NCT01545232 The PROPPR study is a GSD with SSR, funded by the public sector in the USA, investigating the effectiveness
and safety of transfusing patients with severe trauma and major bleeding using plasma, platelets and red
blood cells in a 1 : 1 : 1 ratio compared with a 1 : 1 : 2 ratio. Baraniuk et al. [29] provide the detailed rationale
and design of the trial. The two co-primary outcomes were separately monitored using a two-sided O’Brien
and Fleming [30] boundary with Lan and DeMets [31] alpha spending function based on numbers of events
for each of the two comparisons. SSR was performed prior to the first efficacy interim analysis. Holcomb
et al. [32] report the trial results in the Journal of the AmericanMedical Association.
NCT01336530 The PREVAIL study is a private-sector-funded randomised parallel-group double-blind placebo-controlled
therapeutic confirmatory multicentre trial with four intervention arms, inclusive of the comparator. The trial
is a Bayesian adaptive GSD with two interim analyses, possible SSR after the first or second interim analysis
and drop-the-loser approach (option to drop futile intervention arms). Holmes et al. [33] report the results
of the trial.
NCT00497146 The PRIMO study is a private-sector-funded trial evaluating the effects of a drug (paricalcitol) on cardiac
structure and function over 48 weeks in patients with stage 3/4 chronic kidney disease who had left
ventricular hypertrophy. The trial is an information-based GSD with SSR. Pritchett et al. [34] provide the
design details and rationale, and Thadhani et al. [35] present the findings.
ISRCTN 06473203 The STAR study is a multi-stage operational seamless II/III RCT publicly funded by the NIHR Health
Technology Assessment. The trial investigates the effect of a novel drug-free-interval strategy compared to
the standard treatment strategy in the first-line treatment of advanced renal cell carcinoma [36].
ISRCTN90061564 FOCUS4 is a MAMS seamless II/III design investigating multiple treatments in multiple population enriched
biomarkers in oncology. Kaplan et al. [37] provide a detailed description of the design, its rationale, statistical
properties and implementation tools.
Study characteristics
Frequency and type of ADs Figure 3 provides a bar chart
of the number of ADs per year whilst Fig. 4 provides a
clustered bar chart of the number of ADs per year by
phase. Table 2 shows the number of ADs per 10,000 regis-
tered trials by time period – years were grouped together
due to the small number of ADs – together with a 95 %
CI. This information is also represented on a forest plot
in Fig. 5. On the face of it, it appears that the use of ADs
has increased over time. However, as it has not been pos-
sible to record all ADs, these results should be taken with
caution.
Figure 6 shows a clustered bar chart of the frequency
of ADs by phase and funder. This suggests that ADs are
most commonly used in privately funded phase II trials.
The ratio of private to publicly funded trials appear to be
similar in phases II/III and III.
The type of adaptation undertaken varies according to
phase for both types of funder:
• For phase II trials, GSD and dose selection (DS)
designs are the most common types of adaptation.
• For phase II/III trials, GSD/seamless and DS/seamless
are the most common types of adaptation.
• In phase III trials, GSD is the most common type of
adaptation (Table 3).
Geographic location Figure 7 shows a bar chart of the
number of ADs by geographical location. The majority of
ADs were carried out in the US and Canada, whilst the
number carried out in the UK was similar to the number
carried out in the rest of Europe.
Other study characteristics Across all phases and fun-
ders, ADs are most commonly used in oncology trials.
However, they can be used in a wide range of therapeutic
areas (see Additional file 2). For both sectors, the median
sample size was larger for phase III trials as expected and
the majority of trials investigated one comparator arm
though there were several multi-arm trials (see Additional
file 2).
The main reason for early termination in those trials
that terminated after enrolment was futility (Table 4).
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Fig. 3 Bar chart showing the number of ADs per year. Only complete years are represented. AD adaptive design
The additional data collected for phase III trials showed
that they were all superiority trials and the majority were
parallel in design (one factorial design).
Some characteristics of the trials depend on the source
of funding:
• For private funders, the most common type of
primary outcome is continuous across all phases,
whilst for publicly funded trials the outcome is phase
dependent: continuous being the most common in
phase II trials and binary in phases II/III and III.
• The most common stopping rule is efficacy/safety for
privately funded trials across all phases. In
comparison, for publicly funded trials, the most
common stopping rule differs across phases: efficacy
at phase II and efficacy/safety/futility at phases II/III
and III.
• Privately funded trials are commonly international
studies whilst publicly funded trials are most
commonly national.
• The median duration of the primary outcome is
greatest for phase II/III publicly funded trials and
phase III privately funded trials.
Of the 76 trials that were either completed or termi-
nated after recruitment (as of September 2014), 43 (56 %)
had published their results (as of May 2015). Of these, 27
(63 %) had either published the results within 2 years of
study completion, or published the interim analysis results
before trial completion.
Quality control and efficiency of ClinicalTrials.gov in
capturing ADs
The search of MEDLINE suggests that a number of AD
trials on ClinicalTrials.gov [18] were missed by the search
strategy. Of the 300 randomly selected trials from MED-
LINE, 29 (10 %) satisfied the inclusion criteria, were adap-
tive in design and were registered on ClinicalTrials.gov
[18]. Only one of these (3 %) was captured in the review.
The remaining 28 (97 %) were either registered elsewhere
or there was limited information as to whether or not the
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Fig. 4 Bar chart showing the number of ADs per year by phase. Only complete years are represented. AD adaptive design
trial was registered. Figure 8 shows the screening process
for the MEDLINE search and includes details on the types
of AD found.
Discussion
Main findings
The results suggest that uptake of ADs is now gaining trac-
tion and increasing. Themost popular type of AD in phase
III trials is the GSD. This is most likely because it is well
Table 2 Number of ADs (95 % CI) per 10,000 registered trials per
time period
Year Total number Total number of Number of ADs per 10,000
of ADs registered trials registered trials (95 % CI)
2001–2005 10 9502 11 (4, 17)
2006–2008 37 17,116 22 (15, 29)
2009–2011 50 17,097 29 (21, 37)
2012–2013a 46 11,037 38 (27, 50)
AD adaptive design, CI confidence interval
aResults from 2014 excluded as this was only a partial year
established in the statistical literature and it is described
by regulators as being well understood [12]. Trialists may,
therefore, be more inclined to use designs that they know
well.
Oncology appears to be themain therapeutic area where
ADs are undertaken. This could be for a number of
reasons. Oncology is an area where regulators and the
research community may be receptive to adaptation and
may be more willing to accept such a design. If there are
limitations in current standard care for a type of cancer,
the research community may need to know quickly if a
new treatment is promising so patients can have access to
it and cross over from standard care in the trial. Follow-
ing on from the previous point, it may take a number of
years to get a definitive answer based on survival and so
the research community may be willing to make decisions
on treatment based on interim results on endpoints such
as disease-free survival until the definitive results come in.
Whilst oncology is the main therapeutic area in which
ADs are conducted, there is diversity in the therapeu-
tic area in which ADs can be undertaken (see Additional
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Fig. 5 Forest plot of the number of ADs per 10,000 registered trials by each time period. Only complete years are represented. AD adaptive design
file 2). The underutilisation in some areas may be due
to limited examples of the designs being applied, which
both forms a deterrent and vicious circle. Counter to
this, in oncology, there may be a virtuous circle of trial-
ists having a number of case studies to which they can
refer and so they can see practically how they can be
implemented.
The majority of ADs are phase II trials, which reflects
the literature and regulatory guidance regarding the wide
scope of adaptation in early-phase trials due to the
exploratory nature of the objectives [8, 13, 14]. Whilst
phase II/III and phase III trials were evenly spread across
funders, there was a much higher proportion of pri-
vately funded phase II trials than publicly funded. This is
mainly due to the desire by the private sector to reduce
drug development time and costs [8]. The private sector
may also undertake more early-phase trials, as they often
investigate unlicensed drug interventions, whereas the
interventions studied by the public sector are more var-
ied: licensed and unlicensed treatments as well as health
technologies.
Another important finding is the reason for early termi-
nation of a trial, with futility being the main reason. Fewer
trials stopped early for efficacy suggesting there is a reluc-
tance amongst the involved parties (funders, trialists, and
data monitoring and ethics committees) to stop early. This
possibly could be due to concerns about the robustness
of AD methods when stopping for efficacy. On the other
hand, they may be willing to stop early for futility as it is
good for both ethical and financial reasons. Also, the con-
sequences of stopping early for futility could be perceived
as less pronounced. It could mean a new treatment is no
more effective than usual care so usual care remains as the
standard treatment.
Limitations
The main data source ClinicalTrials.gov [18] posed a few
issues. Firstly, many of the search terms associated with
adaptive methods were redundant in the register. We,
therefore, may have missed some AD trials where the
terminology associated with their methodology was not
used. In addition, some trials were written retrospectively
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Fig. 6 Clustered bar chart showing the number of ADs by phase and funder. AD adaptive design
Table 3 Type of adaptation stratified by phase and funder
Type of adaptation Phase II Phase II/III Phase III All phases
Private Public Private Public Private Public Total
GSD only 10 6 0 2 10 10 38
SSR only 1 0 0 0 4 2 7
DS 25 3 0 0 0 0 28
Dose escalation (DE) 3 2 0 0 1 0 6
Seamless 0 0 3 1 0 0 4
GSD and SSR 1 0 0 0 2 0 3
GSD and DS 13 2 0 1 4 2 22
GSD and DE 1 1 0 0 0 0 2
GSD and seamless 0 0 3 6 0 0 9
SSR and DS 4 1 0 0 0 0 5
Seamless and SSR 0 0 3 2 0 0 5
Seamless and DS 1 0 10 1 0 0 12
Interim analysis 1 0 0 0 0 0 1
Interim analysis and SSR 0 0 0 0 1 0 1
DE dose escalation, DS dose selection, GSD group sequential design, SSR sample size re-estimation
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Fig. 7 Bar chart showing the number of ADs by geographic location. AD adaptive design
into the register and did not state whether interim anal-
ysis, futility assessment using conditional power, or SSR
were planned and carried out, which may have caused us
not to identify some ADs. The search of MEDLINE also
suggests that the search strategy did not capture all ADs,
possibly due to the limited information available on Clin-
icalTrials.gov [18]. The register does not include sections
Table 4 Reasons for early termination of a trial
Reason Phase II Phase II/III Phase III
Private Public Private Public Private Public
Poor recruitment 1 0 1 0 0 1
Efficacy 0 0 0 0 1 0
Futility 3 2 3 0 4 1
Safety 0 0 0 0 0 1
Financial 1 0 1 0 0 0
Other 0 0 0 0 1 0
Alla 5 2 5 0 6 3
aOnly trials terminated after enrolment included
for trialists to provide further information regarding the
nature and scope of any adaptation. For some of the termi-
nated or completed trials, no contact details were available
and so the data extraction could not be performed. Orig-
inally, it was intended to include MRC funded trials as
supplementary material. However, it was not possible to
find an up-to-date list of trials and so these could not be
included in the review. The review highlights ADs that
have been well reported and are readily available through
ClinicalTrials.gov.
In regards to trial designs, it is not possible to dif-
ferentiate between operational and inferential seamless
designs, hence the reason seamless designs have been
grouped into one category in the analysis. This may be
due to confusion or a lack of knowledge of the difference
between operational and inferential seamless designs.
There were fewer SSRs and futility assessments through
conditional power in the review than we expected, pos-
sibly because they are being misclassified or not viewed
as an AD. It was also difficult to find the nature of the
adaptation in phase II trials and to establish whether or
Appendix 10C
Appendix 10C
Hatfield et al. Trials  (2016) 17:150 Page 11 of 13
Reviewed (n = 300)
Excluded (n= 242)
Not adaptive
(n=70)
Phase I/IV (n=126)
Other (n=46)
Adaptive (n=58)
Phase II (n=25) Phase III (n=31)
Phase unknown (n=2)
Type of adaptation:
Simon two stage design
(n=1)
Seamless 2/3 design (n=1)
GSD (n=7)
Dose escalation (n=13)
Bayesian dose selection (n=1)
Futility (n=1)
Dose finding and GSD (n=1)
Type of adaptation:
Bayesian adaptive (n=1)
GSD (n=27)
GSD and dose escalation
(n=1)
Futility (n=1)
Dose escalation (n=1)
Registered:
On clinicaltrials.gov (n=11)
Elsewhere or limited
information available (n=14)
Registered:
On clinicaltrials.gov (n=18)
Elsewhere or limited
information available (n=13)
Captured in the review:
Yes (n=1)
No (n=24)
Captured in the review:
Yes (n=0)
No (n=31)
Fig. 8MEDLINE process. A flow diagram of the MEDLINE search process. GSD group sequential design
not DS/dose escalation (DE) trials were truly adaptive
in design.
Another limitation of the review is that the data sources
used favour publicly funded trials. Whilst we could have
extended our sources to include pharmaceutical company
websites, we did not think it feasible [14] and it may bias
results to companies with better websites.
Recently, an arm of the Food and Drug Administration
reviewed submission protocols and found 136 phase II or
III ADs [23], highlighting underestimation of our review
though the ClinicalTrials.gov [18] register. However, one
point of reassurance is that based on our review, the fre-
quency of certain types of AD, such as GSDs and SSRs, is
consistent with this regulator review.
Finally, chief investigators were only contacted once and
given a deadline of 4 weeks to reply to reducemissing data.
Email reminders could have been sent to reduce missing
data further.
Given the limitations, we do not feel that the results
are invalidated as the objectives were to investigate the
types of AD trials being undertaken and in which thera-
peutic areas. We feel we have achieved this even though
the number of trials is unreported.
Implications and recommendations
The proportion of completed trials that were published
and could be used as case studies is low at only 56 %.
Whilst this is not unique to ADs, it is critical to have case
studies of such complex trials to provide trialists with the
information needed to choose an appropriate AD and to
demystify the fear that ADs are a no-go area. Though we
have not managed to extract an exhaustive list of ADs,
a list of those captured in the review is provided (see
Additional file 3) for trialists to use as practical case stud-
ies. We recommend publishing after completion of a trial
to expand the list of trials available as case studies.
The inability to capture all ADs on ClinicalTrials.gov
[18] using the search terms has highlighted that it is sub-
optimal for the registration of ADs. Since it can take
several years from a trial starting to publishing results,
adequate reporting of ADs in clinical trial registers gives
other trialists the opportunity to see how ADs are cur-
rently being used and perhaps alleviate some of the bar-
riers associated with ADs (for example, that funders and
regulators are against the use of ADs). One of the issues
with ADs is that their point estimates and CIs based
on traditional analysis for fixed designs are biased. An
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important part of clinical research is to undertake system-
atic reviews of the evidence and to do so it is important
to know which studies are adaptive and which are not.
We recommend that clinical trial registers should contain
sections dedicated to the type of AD and scope of the
adaptation, including stopping rules, if this is a feature of
the design. We also suggest that the title of the trial, or
the brief summary or design sections, should contain the
words ‘adaptive design’ so that it can be easily retrieved
in a search. A modification to the CONSORT statement
could help with the improvement of the reporting of AD
trials [24].
Conclusions
The use of ADs appears to be increasing, though we have
not been able to capture all ADs in the review. There may
be disease areas in which ADs are being underutilised and
types of AD not being implemented when they would be
appropriate.
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